Daiichi Sankyo's Q4 2026 earnings call on May 11, 2026 revealed three converging regulatory decisions — for Enhertu (trastuzumab deruxtecan), Datroway (datopotamab deruxtecan), and ifinatamab deruxtecan — that will define the company's near-term revenue trajectory, while a formal pivot toward six next-generation "Breakthrough Generating Technology" platforms signals how Daiichi Sankyo plans to sustain growth beyond the patent expiry of its core DXd antibody-drug conjugate (ADC) franchise. The Q4 2026 earnings presentation also disclosed a HER3-DXd (patritumab deruxtecan) setback in EGFR-mutated lung cancer and a material biomarker-driven redesign of Datroway's non-small cell lung cancer (NSCLC) development program.
Three regulatory decisions define the DSNKY Q4 2026 earnings outlook
Three US FDA decisions, each carrying distinct strategic weight, are expected before the end of calendar year 2026.
The most immediate is Datroway's PDUFA date for first-line triple-negative breast cancer (TNBC), which management said falls in June 2026 based on the TROPION-Breast02 study. Ken Keller, head of the oncology business unit, said the filing has been accepted in the US, Japan, and China, and that the TNBC data — which showed a doubling of overall response rate and an improvement in overall survival in patients ineligible for PD-1 therapy with a combined positive score below 10 — had generated strong anticipation from oncologists. The TNBC approval has been incorporated as a baseline assumption in the company's FY2026 financial forecast, making a rejection or delay a material downside risk to near-term guidance.
The second decision concerns Enhertu in the post-neoadjuvant HER2-positive breast cancer setting, based on the DESTINY-Breast05 (DB05) trial, with a PDUFA date expected in July 2026. That trial, which is also under review in Japan, the EU, and China, demonstrated a clinically meaningful improvement in invasive disease-free survival versus T-DM1 in high-risk patients. Management described the post-neoadjuvant setting, alongside the neoadjuvant data from DESTINY-Breast11, as the foundation for Enhertu's expansion into early-stage breast cancer where, as Keller said, "cure is the goal."
The third decision is the most strategically novel. Ifinatamab deruxtecan (I-DXd), the company's B7-H3-targeting ADC, has been filed with the FDA for second-line extensive-stage small cell lung cancer (ES-SCLC) based on the IDeate-02 study, which showed approximately a 50% overall response rate in previously treated patients. The FDA has granted both Breakthrough Therapy Designation and Priority Review, with a PDUFA date in October 2026. A confirmatory Phase III trial is ongoing. John Tsai, who assumed the role of Global Head of R&D in April 2026, described the IDeate-02 data as "robust" and said the filing represents what would be the company's first approved DXd ADC outside of breast and EGFR-mutated lung cancer indications.
Datroway lung cancer strategy reoriented around TROP-2 biomarker
One of the more consequential signals from the Daiichi Sankyo financial results 2026 presentation was the disclosure that Datroway's NSCLC development program has been materially redesigned following learnings from the TROPION-Lung01 study.
TROPION-Lung01, which evaluated Datroway in previously treated NSCLC, showed that benefit was concentrated in non-squamous patients and that the TROP-2 biomarker correlated with response. Acting on those findings, the company has added TROP-2 NMR-positive status as a primary endpoint for progression-free survival and overall survival in TROPION-Lung05 — the study that supported Datroway's second US approval in EGFR-mutated NSCLC — and has added it as a secondary endpoint in TROPION-Lung08, which is evaluating Datroway in PD-L1-high patients.
A new trial, TROPION-Lung17, was initiated in January 2026 in TROP-2-positive metastatic NSCLC patients in the second-line setting.
Four concurrent first-line NSCLC pivotal trials — AVANZAR, TROPION-Lung07, TROPION-Lung08, and TROPION-Lung10 — are ongoing. Management said H1 2026 readouts are expected from AVANZAR, TROPION-Lung07, and TROPION-Lung15. Tsai acknowledged during the DSNKY investor call in May 2026 that the company has no unblinded data from these trials, and that the biomarker enrichment strategy represents a hypothesis being tested. Keller was explicit that the JPY 3 trillion (USD 19 billion) revenue target for FY2030 is not contingent on any single trial: "AVANZAR could fail. These others could work, and we will be very confident in our ability to deliver on this forecast."
Separately, Datroway entered a new tumor type with the initiation of Urothelial03, a Phase II/III trial in first-line urothelial carcinoma comparing Datroway plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin, started in October 2025.
HER3-DXd setback and acceleration of I-DXd and R-DXd
The DSNKY Q4 2026 earnings call included a notable acknowledgment that HER3-DXd "did not demonstrate positive results in the EGFR-mutated lung cancer area," representing a setback for what had been positioned as the third pillar of the company's DXd ADC franchise. Management said the timing for HER3-DXd's launch has been revised, without specifying a new target.
In contrast, I-DXd and raludotatug deruxtecan (R-DXd) are being accelerated through the Merck collaboration. Beyond the ES-SCLC filing, I-DXd has entered Phase III studies in esophageal cancer and prostate cancer, both initiated in mid-2025. R-DXd, which targets CDH6, received Breakthrough Therapy Designation for platinum-resistant CDH6-expressing ovarian cancer following positive Phase II dose-optimization data from REJOICE-Ovarian-01 presented at ESMO in 2025. Management said regulatory submission is under evaluation, pending expansion of the Phase II dataset.
A first-in-human study for DS-3790, a DXd ADC targeting an undisclosed antigen in relapsed and refractory B-cell lymphoma, was also initiated.
Six BGT platforms outlined as post-DXd growth strategy
A central element of the Daiichi Sankyo earnings call was the presentation of the company's sixth five-year business plan (FY2026–FY2030), which formalized a strategy to identify multiple "Breakthrough Generating Technologies" (BGTs) — defined as proprietary drug discovery platforms capable of generating multiple drugs across diseases — by 2030. Executives expect oncology revenues alone to reach JPY 3 trillion (USD 19 billion) by 2030.
Six BGT candidate platforms were disclosed across two categories.